http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0244358-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6d2313eafffa579301d2112eb2e39f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd47318319f20f7f99d9fef1fd3e511b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1007 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10 |
| filingDate | 2001-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a053978b7d5b0130959f94c263b0d8bc |
| publicationDate | 2002-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-0244358-A2 |
| titleOfInvention | Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 |
| abstract | The invention provides novel MTR-3 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length MTR-3 proteins, the invention further provides isolated MTR-3 fusion proteins, antigenic peptides and anti-MTR-3 antibodies. The invention also provides MTR-3 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an MTR-3 gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of cellular growth or proliferation disorders, e.g., cancer, including, but not limited to colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular growth or proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular growth or proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular growth or proliferation disorder characterized by aberrant MTR-3 polypeptide activity or aberrant MTR-3 nucleic acid expression. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03102143-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004098634-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004098634-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1401475-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03102143-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1401475-A2 |
| priorityDate | 2000-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1069.